External use health care product for reducing intraocular pressure of diabetes mellitus eye diseases

Abstract

The invention relates to an external use health care product for reducing intraocular pressure of diabetes mellitus eye diseases. The external use health care product is characterized by comprising 2-5 milligram of lycium barbarum polysaccharide, 3-7 milligram of rhizoma alismatis polysaccharide, 4-7 milligram of stigma croci total saponins, 4-7 milligram of ginseng total saponins, 15-45 milligram of jasmine total saponins, 3-7 milligram of mannitol, 15-25 milligram of tyloxapol, 15-25 milligram of edetate disodium, 15-25 milligram of potassium chloride, 25-25 milligram of azone, 2-5 milligram of hydrochloric acid or 1-3 milligram of potassium hydroxide (the pH value is adjusted) and 1000-3000 milligram of pure water. The external use health care product can clear liver, improve vision, scatter the liver, purge intense heat, contract pupils, stop pain and lower the intraocular pressure.

Description

technical field [0001] The invention relates to the field of health products, in particular to an external health product for reducing intraocular pressure of diabetic eye disease. Background technique [0002] According to a domestic eye disease epidemiological survey, diabetic eye disease has become a major eye disease in my country. One of the threats of diabetes is microvascular and macrovascular complications caused by long-term poor blood sugar control, which can make patients blind. 40% of people with type 2 diabetes have already developed diabetic retinopathy when they are diagnosed, and 20 years after the diagnosis of diabetes, all people with type 1 diabetes and 60% of people with type 2 diabetes will develop different degrees of diabetic retinopathy. Currently There is no good medicine for diabetic retinopathy, and surgery is generally used for treatment. However, the recovery after surgery is often unsatisfactory, and 80% of patients undergoing surgery will exper...

AI Technical Summary

Problems solved by technology

40% of people with type 2 diabetes have already developed diabetic retinopathy when they are diagnosed, and 20 years after the diagnosis of diabetes, all people with type 1 diabetes and 60% of people with type 2 diabetes will develop different degrees of diabetic retinopathy. Currently There is no good medicine for diabetic retinopathy, and surgery is generally used for treatment. However, the recovery after surgery is often unsatisfactory, and 80% of patients undergoing surgery will experience a sharp increase in intraocular pressure. , patients have symptoms of nausea, dizziness, vomiting, bleeding, and even surgery failures, so it is very valuable to develop health products that reduce intraocular pressure in diabetic eye diseases